NCT02130414View on ClinicalTrials.gov

PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Healthy
Interventions
DRUG

Sandimmun® IV

2 mg/kg IV

DRUG

CyCol® capsules

37.5 mg CyCol® capsules

All Listed Sponsors
lead

Sigmoid Pharma

INDUSTRY

NCT02130414 - PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects | Biotech Hunter | Biotech Hunter